David Degen;Katherine Y. Ebright;Richard H. Ebright
发明人:
Richard H. Ebright,David Degen,Katherine Y. Ebright
申请号：
US14006035
公开号：
US20140018287A1
申请日:
2012.03.19
申请国别(地区):
US
年份:
2014
代理人:
摘要：
It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance.
